<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="235">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217228</url>
  </required_header>
  <id_info>
    <org_study_id>SEB-0121</org_study_id>
    <secondary_id>IDE #G120273</secondary_id>
    <nct_id>NCT02217228</nct_id>
  </id_info>
  <brief_title>Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Randomized, Prospective, Multicenter, Controlled Study With Blinded Assessment to Determine the Safety and Effectiveness of the Sebacia Acne Treatment System in the Treatment of Inflammatory Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sebacia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sebacia, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized multicenter study to examine the safety and effectiveness of Sebacia
      microparticles with or without laser in the treatment of moderate to moderately-severe
      inflammatory acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean percent change in inflammatory lesion count from Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of of adverse events</measure>
    <time_frame>Screening to 12 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in inflammatory lesion count from Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success by Investigator's Global Assessment at Week 12 (defined as 2-point decrease from Baseline IGA)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Inflammatory Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Sebacia microparticles and laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gold microparticle suspension + laser treatment x 3 over the course of two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle suspension and laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vehicle suspension + laser treatment x 3 over the course of two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sebacia microparticles without laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gold microparticle suspension treatment x 3 over the course of two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sebacia microparticles and laser</intervention_name>
    <arm_group_label>Sebacia microparticles and laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vehicle suspension and laser</intervention_name>
    <arm_group_label>Vehicle suspension and laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sebacia microparticles without laser</intervention_name>
    <arm_group_label>Sebacia microparticles without laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 15 - 45 years of age

          -  Able to provide informed consent/assent; minors will provide assent while parent or
             legal guardian will provide consent

          -  Moderate to moderately severe (3 or 4) inflammatory acne vulgaris by Investigator's
             Global Assessment

          -  Subject has 25 to 75 inflammatory lesions on the cheeks, chin and forehead, not
             concentrated in one area

          -  Subject has Fitzpatrick skin phototype I, II or III

          -  Subject is in good health, willing to participate and able to comply with protocol
             requirements

        Exclusion Criteria:

          -  Severe acne (Investigator's Global Assessment 5) with significant scarring potential
             and greater than 2 nodular lesions

          -  Clinically relevant history of keloids

          -  Facial tattoos

          -  Acne conglobata, acne fulminans, chloracne, drug-induced acne

          -  Active concomitant skin disease, excessive scarring or excess facial hair

          -  Heavily tanned skin; unable or unwilling to avoid tanning beds/excessive sun exposure

          -  Acne medication and therapy restrictions - time period prior to Baseline (below)

               1. Oral retinoids - 6 months

               2. Other systemic medications - 4 weeks

               3. Topical retinoids, steroids, antibiotics - 2 weeks

               4. OTC topical treatments - 1 week

               5. Light treatments (including IPL or laser), microdermabrasion and/or peels - 8
                  weeks

               6. Investigational drug, biologic or device - 30 days

               7. Gold therapy of any type for any reason - EXCLUDED

          -  Pregnant, lactating, nursing or planning to become pregnant during the study period

          -  Known allergy to gold, ethanol, diisopropyl adipate, Polysorbate 80

          -  Clinically relevant condition that makes participation unsafe or that would interfere
             with study treatment and assessment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clear Dermatology &amp; Aesthetics Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology &amp; Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dermatology &amp; Laser Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spencer Dermatology</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Dermatology, PC</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Institute-DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser, Skin &amp; Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Skin &amp; Cancer Clinics</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Laser &amp; Surgery Specialists of NY &amp; NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Laser &amp; Skin Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Center of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pflugerville Dermatology Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Dermatology Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>92204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.severeacnestudy.com</url>
    <description>Sebacia Acne Study Website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 31, 2015</lastchanged_date>
  <firstreceived_date>August 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
